Trial · NCT02070991
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Macitentan | Total participants with at least one condition | 7 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Placebo | Total participants with at least one condition | 4 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Macitentan | Participants with fluid retention | 7 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Placebo | Participants with fluid retention | 3 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Macitentan | Participants with worsening in NYHA FC | 1 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Placebo | Participants with worsening in NYHA FC | 2 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Macitentan | Participants with both conditions | 1 | Participants | |
| Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment | Placebo | Participants with both conditions | 1 | Participants | |
| NT-proBNP at Week 12 Expressed as Percent of Baseline NT-proBNP at Rest | Macitentan | 91.56 | 95% Confidence Interval 72.37 to 115.83 | percentage of baseline NT-proBNP | |
| NT-proBNP at Week 12 Expressed as Percent of Baseline NT-proBNP at Rest | Placebo | 118.90 | 95% Confidence Interval 92.53 to 152.78 | percentage of baseline NT-proBNP | |
| PVR at Rest at Week 12 Expressed as Percent of Baseline PVR at Rest | Macitentan | 66.31 | 95% Confidence Interval 56.15 to 78.30 | percentage of baseline PVR | |
| PVR at Rest at Week 12 Expressed as Percent of Baseline PVR at Rest | Placebo | 71.23 | 95% Confidence Interval 51.35 to 98.81 | percentage of baseline PVR | |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Macitentan | mPAP at baseline | 44.6 | 95% Confidence Interval 40.7 to 48.6 | mmHg |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Placebo | mPAP at baseline | 45.9 | 95% Confidence Interval 41.7 to 50.1 | mmHg |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Macitentan | mPAP at Week 12 | 41.1 | 95% Confidence Interval 36.2 to 46.0 | mmHg |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Placebo | mPAP at Week 12 | 42.1 | 95% Confidence Interval 37.5 to 46.7 | mmHg |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Macitentan | Change in mPAP from baseline to Week 12 | -3.5 | 95% Confidence Interval -6.1 to -0.9 | mmHg |
| Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP) | Placebo | Change in mPAP from baseline to Week 12 | -3.8 | 95% Confidence Interval -7.5 to -0.1 | mmHg |
| Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP) | Macitentan | mRAP at baseline | 12.1 | 95% Confidence Interval 10.0 to 14.3 | mmHg |
| Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP) | Placebo | mRAP at baseline | 13.0 | 95% Confidence Interval 11.0 to 14.9 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02070991/results